Grifols, ES0171996087

JPMorgan cuts target to USD 9.00 for Grifols stock

Published on 10/27/2026 at 16:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Three analysts rate Grifols Hold or Sell, while consensus is Reduce. Grifols stock costs EUR 10.70 on October 27, 2026 at 4:30 p.m. CEST.

Analyst target and reporting date

  • JPMorgan cut its Grifols target by USD 1.00 on October 26, 2026.
  • Three analysts hold or sell the stock, while the consensus rating is Reduce.
  • Grifols stock costs EUR 10.70 at Lang & Schwarz on October 27, 2026 at 4:30 p.m. CEST.
  • Grifols is scheduled to report third-quarter results on November 10, 2026.
Grifols, ES0171996087, Illustration mit AI erstellt.

JPMorgan cut its Grifols price target from USD 10.00 to USD 9.00 on October 26, 2026, while maintaining a neutral rating, according to MarketBeat. Grifols stock was trading at EUR 10.70 at Lang & Schwarz on October 27, 2026 at 4:30 p.m. CEST.

JPMorgan trims its target

The move leaves the target USD 1.00 below its previous level. MarketBeat also reports a consensus Reduce rating, with two analysts at Hold and one at Sell, giving the latest view a cautious tilt.

What does the target imply?

The Nasdaq-listed Grifols ADR stood at USD 7.93 at 11:32 a.m. EDT on October 27, 2026. Against that separate dollar quotation, JPMorgan's USD 9.00 target is 13.49 percent above the ADR price. The euro quotation remains the reference for investors trading the stock through German venues.

Results date sets the next marker

Gekko lists November 10, 2026 as Grifols' next earnings date. The company develops plasma-derived medicines and diagnostic technologies, including immunoglobulins, albumin and coagulation factors, according to MarketBeat.

Recent operating backdrop

Grifols reported first-half 2026 revenue of EUR 3.57 billion and net profit of EUR 227.00 million in its investor materials dated July 28, 2026. Revenue increased 2.60 percent at constant currency, while net profit rose 28.70 percent. The figures provide the operating backdrop for the next report, although they are not a new October event.

Stock position

The euro quotation places Grifols in a higher trading zone than its recent pre-market levels, but the next material checkpoint is the November reporting date. JPMorgan's lower target and the Reduce consensus give investors a concrete valuation reference without resolving the wider outlook.

The further course of trading is shown by the continuously updated real-time quote of Grifols stock.

Grifols market facts

  • Company: Grifols, S.A.
  • ISIN: ES0171996087
  • Ticker: GRF
  • Primary exchange: Madrid Stock Exchange
  • Price Lang & Schwarz (as of October 27, 2026, 4:30 p.m. CEST): EUR 10.70
  • Sector / Industry: Healthcare / Biotechnology
  • Next earnings date: November 10, 2026

Market context: Market report IBEX 35.

More news and analyses on Grifols stock

Disclaimer...
en | ES0171996087 | GRIFOLS | boerse | 70421509 |